Neuralstem (NASDAQ:CUR) had its price objective dropped by equities researchers at S&P Equity Research from $2.26 to $1.91 in a research report issued on Thursday.

Shares of Neuralstem (NASDAQ:CUR) traded up $0.09 on Thursday, hitting $1.91. The stock had a trading volume of 504,100 shares, compared to its average volume of 328,714. The company has a market cap of $33.98, a P/E ratio of -1.15 and a beta of 1.60. Neuralstem has a 12-month low of $0.88 and a 12-month high of $6.60.

Large investors have recently added to or reduced their stakes in the stock. National Asset Management Inc. grew its stake in Neuralstem by 9.2% in the second quarter. National Asset Management Inc. now owns 22,985 shares of the company’s stock worth $134,000 after purchasing an additional 1,937 shares during the period. Blair William & Co. IL grew its stake in Neuralstem by 171.0% in the second quarter. Blair William & Co. IL now owns 87,343 shares of the company’s stock worth $506,000 after purchasing an additional 55,115 shares during the period. Alethea Capital Management LLC purchased a new stake in Neuralstem in the first quarter worth $868,000. Vanguard Group Inc. boosted its holdings in Neuralstem by 1.1% in the second quarter. Vanguard Group Inc. now owns 345,346 shares of the company’s stock worth $2,000,000 after acquiring an additional 3,853 shares in the last quarter. Finally, Sabby Management LLC bought a new stake in Neuralstem in the second quarter worth $1,893,000. Institutional investors own 7.05% of the company’s stock.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with's FREE daily email newsletter.